Loading clinical trials...
Loading clinical trials...
Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect) - A Real-world, Prospective, Observational Study of the Effectiveness of Deucravacitinib in Adults With Moderate-to-Severe Plaque Psoriasis in France
The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Local Institution - 060
Amiens, France
Cabinet Médical Elisabeth Lion
Angers, France
Local Institution - 045
Argenteuil, France
CH ARRAS
Arras, France
Local Institution - 041
Bordeaux, France
Local Institution - 048
Bordeaux, France
Centre Hospitalier William Morey - Hématologie
Chalon-sur-Saône, France
CHU Dijon
Dijon, France
Local Institution - 077
Dijon, France
Local Institution - 011
La Tronche, France
Start Date
January 29, 2025
Primary Completion Date
April 30, 2028
Completion Date
April 30, 2028
Last Updated
April 11, 2025
350
ESTIMATED participants
Deucravacitinib
DRUG
First line of the email MUST contain NCT # and Site #.
CONTACT
Lead Sponsor
Bristol-Myers Squibb
NCT07449234
NCT07116967
NCT07250802
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions